These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7963690)

  • 1. Development of ribozymes for gene therapy.
    Sullivan SM
    J Invest Dermatol; 1994 Nov; 103(5 Suppl):85S-89S. PubMed ID: 7963690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages.
    Shimayama T; Nishikawa F; Nishikawa S; Taira K
    Nucleic Acids Res; 1993 Jun; 21(11):2605-11. PubMed ID: 8332458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic applications of ribozymes.
    Kijima H; Ishida H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
    Pharmacol Ther; 1995; 68(2):247-67. PubMed ID: 8719970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-gene therapy: the use of ribozymes to inhibit gene function.
    Couture LA; Stinchcomb DT
    Trends Genet; 1996 Dec; 12(12):510-5. PubMed ID: 9257533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy.
    Hampel A
    Prog Nucleic Acid Res Mol Biol; 1998; 58():1-39. PubMed ID: 9308362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribozymes. Their functions and strategies for their use.
    Gibson SA; Shillitoe EJ
    Mol Biotechnol; 1997 Apr; 7(2):125-37. PubMed ID: 9219227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribozymes as therapeutic tools for genetic disease.
    Phylactou LA; Kilpatrick MW; Wood MJ
    Hum Mol Genet; 1998; 7(10):1649-53. PubMed ID: 9735387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribozymes and siRnas: from structure to preclinical applications.
    Sioud M
    Handb Exp Pharmacol; 2006; (173):223-42. PubMed ID: 16594618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA enzymes (ribozymes) as antiviral therapeutic agents.
    Rossi JJ; Sarver N
    Trends Biotechnol; 1990 Jul; 8(7):179-83. PubMed ID: 1366622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes.
    Amarzguioui M; Brede G; Babaie E; Grotli M; Sproat B; Prydz H
    Nucleic Acids Res; 2000 Nov; 28(21):4113-24. PubMed ID: 11058107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of ribozymes expressed using U1 and T7 vectors for the intracellular cleavage of ANF mRNA.
    De Young MB; Kincade-Denker J; Boehm CA; Riek RP; Mamone JA; McSwiggen JA; Graham RM
    Biochemistry; 1994 Oct; 33(40):12127-38. PubMed ID: 7918434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic applications of catalytic antisense RNAs (ribozymes).
    Rossi JJ
    Ciba Found Symp; 1997; 209():195-204; discussion 204-6. PubMed ID: 9383577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Degradation of hammerhead ribozymes by human ribonucleases.
    Qiu L; Moreira A; Kaplan G; Levitz R; Wang JY; Xu C; Drlica K
    Mol Gen Genet; 1998 May; 258(4):352-62. PubMed ID: 9648739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-viral delivery of ribozymes for cancer gene therapy.
    Kashani-Sabet M
    Expert Opin Biol Ther; 2004 Nov; 4(11):1749-55. PubMed ID: 15500403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
    Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
    Nucleic Acids Res; 1997 Aug; 25(15):3074-81. PubMed ID: 9224607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
    Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
    Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems.
    Rossi JJ; Elkins D; Zaia JA; Sullivan S
    AIDS Res Hum Retroviruses; 1992 Feb; 8(2):183-9. PubMed ID: 1540406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and testing of ribozymes for cancer gene therapy.
    Norris JS; Hoel B; Voeks D; Maggouta F; Dahm M; Pan W; Clawson G
    Adv Exp Med Biol; 2000; 465():293-301. PubMed ID: 10810634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.